Xu Chen, Liu Yalan, Huang Jie, Wang Hao, Tan Lijie, Xu Yifan, Jiang Zhengzeng, Wang Xin, Hou Yingyong, Jiang Dongxian, Wang Qun
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Oncotarget. 2017 Sep 23;8(50):87699-87709. doi: 10.18632/oncotarget.21181. eCollection 2017 Oct 20.
copy number variations have been reported to be associated with cancer prognosis in several cancers. However, the role of gain has not yet been determined in esophageal squamous cell carcinomas (ESCC).
Fluorescence hybridization (FISH) for was performed on 262 ESCC samples using tissue microarray (TMA).
The median age of ESCC patients was 62 years (range 37-83), with frequencies between women (16.4%) and men (83.6%). Of the 262 tumors, 77 tumors (29.4%) had high gain. In the multivariate analysis, lymph node metastasis (HR: 3.236, <0.001 for DFS; HR: 3.501, <0.001 for OS) and clinical stage (HR: 3.388, <0.001 for DFS; HR: 3.616, <0.001 for OS) were identified as independent worse prognostic factors. Interestingly, among patients without lymph node metastasis or stage I-II patients, high gain was associated with better DFS (=0.009 or 0.046) and OS (=0.014 or 0.069) after disease free survival time was more than or equal to 12 months. Reversely, among patients with lymph node metastasis or stage III-IVa patients, high gain was associated with poorer DFS (=0.007 or 0.021) and OS (=0.029 or 0.068) after disease free survival time was more than or equal to 29 months.
We observed that high gain had bidirectional prognostic significance in ESCC patients with different lymph node status or clinical stage. These findings might provide the useful way of detailed risk stratification in patients with ESCC, and an insight into pathogenesis and mechanism of progression in ESCC.
据报道，拷贝数变异与多种癌症的预后相关。然而，在食管鳞状细胞癌（ESCC）中，扩增的作用尚未确定。
使用组织微阵列（TMA）对262例ESCC样本进行荧光原位杂交（FISH）检测。
ESCC患者的中位年龄为62岁（范围37 - 83岁），女性患者占比16.4%，男性患者占比83.6%。在262例肿瘤中，77例（29.4%）存在高扩增。多因素分析显示，淋巴结转移（DFS的HR：3.236，P < 0.001；OS的HR：3.501，P < 0.001）和临床分期（DFS的HR：3.388，P < 0.001；OS的HR：3.616，P < 0.001）是独立的不良预后因素。有趣的是，在无淋巴结转移的患者或I - II期患者中，无病生存期大于或等于12个月后，高扩增与更好的DFS（P = 0.009或0.046）和OS（P = 0.014或0.069）相关。相反，在有淋巴结转移的患者或III - IVa期患者中，无病生存期大于或等于29个月后，高扩增与较差 的DFS（P = 0.007或0.021）和OS（P = 0.029或0.068）相关。
我们观察到，高扩增在不同淋巴结状态或临床分期的ESCC患者中具有双向预后意义。这些发现可能为ESCC患者提供详细风险分层的有用方法，并有助于深入了解ESCC的发病机制和进展机制。
